Organization | Belarusian Medical Academy of Post-Graduate Education

Belarusian Medical Academy of Post-Graduate Education Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2013

NCT02140073

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Belarusian Medical Academy of Post-Graduate Education

Active Ingredients

Drugs in Phase 4 Trials (2)

domperidone (1 trial)

omeprazole (prilosec) (1 trial)

Drugs in Phase 2 Trials (5)

allogeneic mesenchymal stem cells (2 trials)

allogenic mesenchymal stem cell derived from olfactory mucosa (1 trial)

autologous keratinocytes (1 trial)

autologous mesenchymal stem cells (4 trials)

autologous skin fibroblasts (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Burns (Phase 2)

Chronic Periodontitis (Phase 2)

Constriction, Pathologic (Phase 2)

Endometritis (Phase 2)

Gastroesophageal Reflux (Phase 4)

Gingival Recession (Phase 2)

Gynatresia (Phase 2)

Laryngostenosis (Phase 2)

Parkinson Disease (Phase 2)

Periodontitis (Phase 2)

Tracheal Stenosis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 7